Array second quarter revenue increases to $23.

Array second quarter revenue increases to $23 .2 million Array BioPharma Inc. today reported economic results for the second quarter of fiscal 2012. Array reported revenue of $23.2 million for the next quarter of fiscal 2012, compared to revenue of $16.5 million for the same period in fiscal 2011. The web loss was significantly decreased to $3.8 million, or per talk about, for the next quarter, in comparison to a net lack of $12.4 million, or per share, for the second quarter in fiscal 2011.

Aridis’ Aerucin gets FDA Fast Monitor Designation for treatment of hospital-acquired and ventilator-associated pneumonia Aridis Pharmaceuticals, Inc., a biopharmaceutical organization applying proprietary technology to produce novel treatments for infectious diseases, today that the U announced.S. Aridis completed dosing and enrollment in a Phase 1 clinical study of Aerucin. Results are expected in the fourth quarter of this year. Vu Truong, Ph.D., CEO and Founder of Aridis, mentioned, We are pleased to receive Fast Monitor designation for Aerucin as it provides an accelerated advancement and regulatory review pathway, and if approved, can lead to expedited availability of Aerucin to critically ill individuals with hospital-acquired and ventilator-associated pneumonia.